US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nxera Pharma Co.,Ltd.

6.79

+0.851014.33%

Volume:1.07K

Turnover:6.87K

Market Cap:610.52M

PE:-9.55

High:6.79

Open:6.40

Low:6.40

Close:5.94

52wk High:10.62

52wk Low:5.50

Shares:89.90M

Float Shares:66.02M

Volume Ratio:1.67

T/O Rate:0.00%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.7107

EPS(LYR):-0.6184

ROE:-4.85%

ROA:-1.88%

PB:1.37

PE(LYR):-10.98

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025

Nxera Pharma’s Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia

Nxera Pharma’s Partner Tempero Bio Initiates Phase 2 Trial with TMP-301 for Alcohol Use Disorder

Nxera Pharma Enters Agreement with Holling to Commercialize Daridorexant in Taiwan

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SOLTF"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SOLTF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SOLTF\",,,,,undefined,":{"symbol":"SOLTF","market":"US","secType":"STK","nameCN":"Nxera Pharma Co.,Ltd.","latestPrice":6.791,"timestamp":1755528860396,"preClose":5.94,"halted":0,"volume":1073,"delay":15,"floatShares":66017259,"shares":89901584,"eps":-0.71075,"marketStatus":"Trading","change":0.851,"latestTime":"08-18 10:54:20 EDT Delay","open":6.4,"high":6.791,"low":6.4,"amount":6868.764,"amplitude":0.065825,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.71075,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1755547200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"PINK LIMITED","adjPreClose":5.94,"volumeRatio":1.666317},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SOLTF\",,,,,undefined,":{"symbol":"SOLTF","floatShares":66017259,"roa":"-1.88%","roe":"-4.85%","lyrEps":-0.618397,"volumeRatio":1.666317,"shares":89901584,"dividePrice":0,"high":6.791,"amplitude":0.065825,"preClose":5.94,"low":6.4,"week52Low":5.5,"pbRate":"1.37","psRate":"2.89","week52High":10.62,"institutionHeld":0,"latestPrice":6.791,"eps":-0.71075,"divideRate":0,"volume":1073,"delay":15,"ttmEps":-0.71075,"open":6.4,"prevYearClose":6.1575,"prevWeekClose":5.94,"prevMonthClose":6.2,"prevQuarterClose":6.6,"fiveDayClose":6.5,"twentyDayClose":5.69,"sixtyDayClose":5.91},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SOLTF\",params:#limit:5,,,undefined,":[{"date":"2024-05-09","symbol":"SOLTF","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1715241600000,"name":null,"time":"","dateTimestamp":1715227200000,"actualEps":null},{"market":"US","date":"2023-11-10","symbol":"SOLTF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1699592400000,"reportTimeType":"","actualEps":null},{"date":"2022-11-11","symbol":"SOLTF","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1668157200000,"name":null,"time":"Pre-Market","dateTimestamp":1668142800000,"actualEps":null},{"market":"US","date":"2022-08-10","symbol":"SOLTF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1660104000000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SOLTF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SOLTF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3,"buy":0.6,"hold":0.1,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":10,"updateTime":1731816000000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SOLTF\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532987928","title":"Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2532987928","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532987928?lang=en_us&edition=fundamental","pubTime":"2025-05-02 14:30","pubTimestamp":1746167400,"startTime":"0","endTime":"0","summary":"Tokyo, Japan and Cambridge, UK, 2 May 2025 – Nxera Pharma  provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2025. The full report can be found here.Chris Cargill, President and CEO of Nxera, commented: “As we mark one year since our transformation from Sosei Heptares to Nxera Pharma, I am incredibly proud of the progress we’ve made and how we have evolved. Our new identity has unified the Group and helped clarify our mission while clearly signalling our intent to lead the next era of biopharmaceutical innovation in Japan and globally. The strides we’ve made over the past year is a testament to the strength of our people, our partnerships, and the power of our NxWave platform to deliver promising new candidates for development across major disease areas with great unmet need.“We expect 2025 to be an important year across both for our partnered and in-house portfolios. With key data readouts anticipated from multiple c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nxera-pharma-operational-highlights-consolidated-063000127.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CNSL","BK4115","SOLTF","BK4233","BK4528","UK","BK4007","BK4205"],"gpt_icon":0},{"id":"2532742015","title":"Nxera Pharma’s Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2532742015","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532742015?lang=en_us&edition=fundamental","pubTime":"2025-05-01 07:35","pubTimestamp":1746056100,"startTime":"0","endTime":"0","summary":"NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with Neurocrine. For more information, please read Neurocrine’s announcement . About NBI-1117568 NBI-1117568 is the first and only investigational oral muscarinic M4 selective orthosteric agonist in clinical development for the treatment of schizophrenia. There are five muscarinic acetylcholine receptors involved in neurotransmission. Muscarinic receptors are central to brain function and validated as drug targets in psychosis and cognitive disorders. As an M4 selective orthosteric agonist, NBI-1117568 offers the potential for a novel mechanism with an improved safety profile without the n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nxera-pharma-partner-neurocrine-biosciences-233500668.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","NBIX","LU2065171311.SGD","LU0109394709.USD","LU0320765992.SGD","BK4233","SOLTF","UK","NBI","BK4205","LU2065171402.SGD","LU2065169927.USD","LU0889565916.HKD","LU2065170008.USD","LU2324357040.USD","BK4528","BK4007","LU0823416689.USD"],"gpt_icon":0},{"id":"2522827038","title":"Nxera Pharma’s Partner Tempero Bio Initiates Phase 2 Trial with TMP-301 for Alcohol Use Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2522827038","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522827038?lang=en_us&edition=fundamental","pubTime":"2025-03-25 08:05","pubTimestamp":1742861100,"startTime":"0","endTime":"0","summary":"Tokyo, Japan and Cambridge, UK, 25 March 2025 – Nxera Pharma Co., Ltd.  announces that its partner Tempero Bio, Inc. has initiated a Phase 2 trial of TMP-301, a potent, selective and orally available mGluR5 negative allosteric modulator , for the treatment of alcohol use disorder . The full announcement from Tempero Bio can be found by clicking here, in which Tempero Bio also announces the close of a $70 million financing, the proceeds of which will be used to advance TMP-301 through the Phase 2 trial for alcohol use disorder and a second Phase 2 trial in cocaine use disorder planned to start over the next year. The funds will also be used by Tempero Bio to conduct Phase 3-enabling activities for TMP-301 and preclinical studies for additional indications and formulations.In addition to several products being commercialized in Japan, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nxera-pharma-partner-tempero-bio-000500210.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4233","TMP","UK","BK4211","SOLTF","BK4528","BK4205"],"gpt_icon":0},{"id":"2514340316","title":"Nxera Pharma Enters Agreement with Holling to Commercialize Daridorexant in Taiwan","url":"https://stock-news.laohu8.com/highlight/detail?id=2514340316","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514340316?lang=en_us&edition=fundamental","pubTime":"2025-02-28 15:42","pubTimestamp":1740728520,"startTime":"0","endTime":"0","summary":"Daridorexant is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep disorders, such as insomnia. Filing of daridorexant in Taiwan planned for 2025, and launch, if approved, is expected during 2026. Under the terms of the agreement, Nxera will be responsible for the supply of drug product and Holling will be responsible for regulatory, commercial and distribution activities and will hold all regulatory approvals. Holling expects to file a New Chemical Entity  to the Taiwan Food and Drug Administration  in mid-2025, which if approved would lead to an expected launch in mid-2026.About Daridorexant Daridorexant is a dual orexin receptor antagonist that blocks the binding and activity of the wake-promoting neuropeptides known as orexins. Daridorexant 25mg and 50mg was approved in Japan in September 2024 and launched under the brand name of QUVIVIQ by Nxera Pharma Japan  and Shionogi in December 2024. Nxera is also conducting a Pha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nxera-pharma-enters-agreement-holling-074200001.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","UK","BK4205","BK4528","SOLTF","BK4233"],"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/SOLTF\",params:#limit:6,delay:false,,,undefined,":[]}}